Goldline Pharmaceutical
add_icon

Goldline Pharmaceutical

33.00
+0.65
(2.01%)
Market Cap
31.72 Cr
PE Ratio
-
Volume
15,000.00
Day High - Low
33.00 - 32.41
52W High-Low
60.00 - 31.62
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
31.72 Cr
EPS
5.97
PE Ratio
-
PB Ratio
1.29
Book Value
25.05
EBITDA
6.90
Dividend Yield
0.00 %
Industry
-
Sector
-
Return on Equity
28.89
Debt to Equity
0.82
Forecast For
Actual

Company News

View All News
Caret
positive
Goldline Pharmaceutical Ltd promoter Amol Laxmikant Mujumdar acquired 18,000 equity shares via open market purchase on September 1, 2026. His stake rose to 29.46%.
positive
Promoter Amol Mujumdar acquired 60,000 equity shares of Goldline Pharmaceutical Ltd via open market purchase on August 31, 2026, raising stake to 29.27%.
neutral
Goldline Pharmaceutical shareholders passed all eight resolutions at its 22nd AGM on August 29, 2026. Key approvals include related-party transactions and unsecured loans from directors.
View more
Growth Rate
Revenue Growth
11.03 %
Net Income Growth
46.43 %
Cash Flow Change
-11.64 %
ROE
5.55 %
ROCE
3.95 %
EBITDA Margin (Avg.)
7.02 %

Yearly Financial Results

Annual Financials
2023
2024
2025
2026
Revenue
20
24
28
31
Expenses
18
19
22
24
EBITDA
2
4
6
7
Operating Profit %
11 %
18 %
21 %
22 %
Depreciation
0
0
0
0
Interest
2
2
2
1
Profit Before Tax
0
3
4
5
Tax
0
1
1
1
Net Profit
0
2
3
4
EPS in ₹
0.43
3.01
4.11
5.97

Balance Sheet

Balance Sheet
2023
2024
2025
2026
Total Assets
19
23
26
29
Fixed Assets
3
3
3
3
Current Assets
17
20
23
26
Capital Work in Progress
0
0
0
0
Investments
0
0
0
0
Other Assets
17
20
23
26
Total Equity & Liabilities
19
23
26
29
Current Liabilities
9
10
12
12
Non Current Liabilities
5
5
4
3
Total Equity
6
8
10
14
Reserve & Surplus
2
4
2
6
Share Capital
4
4
9
9

Cash Flow

Cash Flow
2023
2024
2025
2026
Net Cash Flow
-0
1
0
-1
Investing Activities
-1
-1
0
-0
Operating Activities
2
3
3
3
Financing Activities
-1
-1
-3
-3

Share Holding

% Holding
Sept 2025
May 2026
Promoter
79.71 %
79.71 %
FIIs
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
Government
0.00 %
0.00 %
Public / Retail
0.00 %
0.00 %
Others
20.29 %
20.29 %
No of Share Holders
20
20

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
09 Jun 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Jun 2026 46.03 44.20
29 Aug 2026 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Aug 2026 39.00 40.97

Announcements

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 02, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 02, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Sep 01, 2026
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 31, 2026
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 29, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 29, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 29, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2026
Intimation Of Record Date For Remote E-VotingAug 06, 2026
Intimation Of Book Closure Shall Remain Closed From Sunday 23Rd August 2026 To Saturday 29Th August 2026 (Both Days Inclusive) For Taking Record Of The Members Of The Company For The Purpose Of 22Nd (Twenty Second) Annual General Meeting Of The Company ScAug 06, 2026
Reg. 34 (1) Annual Report.Aug 06, 2026
Intimation Of Notice Of 22Nd Annual General Meeting Of Goldline Pharmaceutical Limited Will Be Held On Saturday 29Th August 2026 At 4:00 P.M. At Hotel Airport Centre Point 131/1 Adjacent To Airport Wardha Road Somalwada Nagpur Maharashtra 440025Aug 06, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 30, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 20, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJul 14, 2026
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AJun 24, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 24, 2026
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 24, 2026
Disclosure Under Regulation 29 (2) Of Securities And Exchange Board Of India (Substantial Acquisition Of Shares And Takeovers) Regulations 2011Jun 23, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJun 09, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 09Th June 2026Jun 09, 2026
Outcome Of Board Meeting Held Today I.E. 09Th June 2026Jun 09, 2026
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 To Be Held On Tuesday June 09 2026.Jun 02, 2026
Closure of Trading WindowMay 27, 2026
Listing of Equity Shares of Goldline Pharmaceutical LtdMay 19, 2026

Technical Indicators

RSI(14)
Neutral
26.29
ATR(14)
Less Volatile
1.58
STOCH(9,6)
Oversold
16.86
STOCH RSI(14)
Oversold
0.00
MACD(12,26)
Bearish
-0.64
ADX(14)
Strong Trend
29.59
UO(9)
Bearish
42.43
ROC(12)
Downtrend And Accelerating
-20.90
WillR(14)
Oversold
-92.22